Chuck Simonton, MD, reviews that in October 2022 the FDA accepted and closed all Impella post-approval studies for high-risk PCI, cardiogenic shock, post-cardiotomy cardiogenic shock and right heart failure.
Gregg Stone, MD, FACC, FSCAI interviews Prof. Divaka Perera, professor of cardiology at Kings College in London, UK at the European Society of Cardiology (ESC) Congress 2022 in Barcelona, Spain.